Dual FAAH and MAGL inhibition might play a key role in visceral pain

References (1)

1. Nahin RL. Estimates of Pain Prevalence and Severity in Adults: United States, 2012. J Pain 2015; 16: 769-80. [CrossRef] Guindon J, Walczak JS, Beaulieu P. Recent advances in the pharma- cological management of pain. Drugs 2007; 67: 2121-33. [CrossRef] Guindon G, Hohmann A. The Endocannabinoid System and Pain. CNS Neurol Disord Drug Targets 2009; 8: 403-21. [CrossRef] Woodhams SG, Chapman V, Finn DP, Hohmann AG, Neugebauer V. The cannabinoid system and pain. Neuropharmacology 2017; 124: 105-20. [CrossRef] Sakin YS, Dogrul A, Ilkaya F, Seyrek M, Ulas UH, Gulsen M, Bag- ci S. The effect of FAAH, MAGL, and Dual FAAH/MAGL inhibition on inflammatory and colorectal distension-induced visceral pain models in Rodents. Neurogastroenterol Motil 2015; 27: 936-44. [CrossRef] Anderson WB, Gould MJ, Torres RD, Mitchell VA, Vaughan CW. Actions of the dual FAAH/MAGL inhibitor JZL195 in a murine in- flammatory pain model. Neuropharmacology 2014; 81: 224-30. [CrossRef] Long JZ, Nomura DK, Vann RE, et al. Dual blockade of FAAH and MAGL identifies behavioral processes regulated by endo- cannabinoid crosstalk in vivo. Proc Natl Acad Sci USA 2009; 106: 20270-5. [CrossRef]